Article

Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia

2025-10-15

Abstract excerpt

Predictive biomarkers can potentially meet the need for improved drug assignment in acute myeloid leukemia (AML). Fewer than half of AML patients have actionable mutations: consequently, targeted therapy achieves remission in only a fraction of those who have them. Dynamic BH3 Profiling (DBP), a functional assay, can measure changes in ex vivo drug-induced apoptotic priming in multiple cancers. To assess the feas...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1f74c243-8ff2-5e42-a75a-3e4e242acff8
DOI: 10.1101/2025.10.14.682414

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemiaDOI 10.1101/2025.10.14.682414Read

Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemiaSemantic proximity Read

The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.Semantic proximity Read

Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed MyeloblastsSemantic proximity Read

Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemiaSemantic proximity Read

Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.Semantic proximity Read

Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7 + 3.Semantic proximity Read

Integrating ex vivo drug sensitivity and genetic mutation analysis improves prediction of chemotherapy response in acute myeloid leukemia.Semantic proximity Read

Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AMLSemantic proximity Read

Single cell guided deconvolution of bulk transcriptomics recapitulates differentiation stages of acute myeloid leukemia and predicts drug responseSemantic proximity Read

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.Semantic proximity Read

A precision medicine approach to management of acute myeloid leukemia in older adults.Semantic proximity Read

Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular EraSemantic proximity Read